IBRX (ImmunityBio, Inc.) Stock Financials & Earnings | Market Cap Arena

IBRX (ImmunityBio, Inc.) Stock Financials & Earnings | Market Cap Arena

IBRXImmunityBio, Inc.

Mkt Cap$8B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$113M

Net Income (TTM)-$351M

EPS (TTM)-$0.38

Free Cash Flow (TTM)-$307M

Gross Margin92.4%

Op. Margin-226.0%

Net Margin-310.2%

FCF Margin-271.1%

P/S Ratio (TTM)73.0x

P/E Ratio (TTM)—

YoY Rev Growth+668.3%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$360K	-$6M	-$112M
Q2 23	$41K	$41K	-$85M
Q3 23	$82K	$82K	-$80M
Q4 23	$139K	$139K	-$85M
Q1 24	$40K	$40K	-$95M
Q2 24	$1M	$1M	-$99M
Q3 24	$6M	$6M	-$80M
Q4 24	$8M	$8M	-$69M
Q1 25	$17M	$16M	-$64M
Q2 25	$26M	$26M	-$71M
Q3 25	$32M	$28M	-$56M
Q4 25	$38M	$34M	-$65M

Valuation

Quarter	P/S	P/E
Q1 23	14105.8x	—
Q2 23	13962.8x	—
Q3 23	14866.9x	—
Q4 23	13289.4x	—
Q1 24	27370.9x	—
Q2 24	6319.6x	—
Q3 24	1127.4x	—
Q4 24	560.6x	—
Q1 25	264.7x	—
Q2 25	146.0x	—
Q3 25	100.1x	—
Q4 25	73.0x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$84M	-$93M
Q2 23	-$80M	-$88M
Q3 23	-$87M	-$93M
Q4 23	-$115M	-$123M
Q1 24	-$107M	-$108M
Q2 24	-$100M	-$101M
Q3 24	-$99M	-$102M
Q4 24	-$85M	-$87M
Q1 25	-$86M	-$87M
Q2 25	-$80M	-$81M
Q3 25	-$69M	-$69M
Q4 25	-$70M	-$70M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$8M
Q2 23	$9M
Q3 23	$6M
Q4 23	$8M
Q1 24	$1M
Q2 24	$724K
Q3 24	$3M
Q4 24	$2M
Q1 25	$1M
Q2 25	$1M
Q3 25	$0
Q4 25	$0

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+2471.4%	+16.6%
Q2 23	+17.1%	+6.9%
Q3 23	-30.5%	-11.8%
Q4 23	+90.4%	+1.5%
Q1 24	-88.9%	-14.9%
Q2 24	+2453.7%	+17.8%
Q3 24	+7346.3%	+7.7%
Q4 24	+5333.1%	-10.0%
Q1 25	+41192.5%	-15.0%
Q2 25	+2423.9%	-2.7%
Q3 25	+425.1%	+1.5%
Q4 25	+407.0%	+33.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$11M	3021.7%
Q2 23	$11M	26980.5%
Q3 23	$14M	17620.7%
Q4 23	$13M	9189.9%
Q1 24	$8M	20665.0%
Q2 24	$10M	920.6%
Q3 24	$7M	122.6%
Q4 24	$9M	119.7%
Q1 25	$10M	57.7%
Q2 25	$10M	36.5%
Q3 25	$0	0.0%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 23	$79M	$27M
Q2 23	$53M	$32M
Q3 23	$48M	$32M
Q4 23	$52M	$33M
Q1 24	$53M	$42M
Q2 24	$51M	$49M
Q3 24	$50M	$36M
Q4 24	$35M	$42M
Q1 25	$48M	$33M
Q2 25	$55M	$42M
Q3 25	$51M	$33M
Q4 25	$61M	$38M

Revenue Segments

Quarter	Product	Product and Service, Other
Q2 24	$990K	$57K
Q3 24	$6M	$152K
Q1 25	$17M	$8K
Q2 25	$26M	$4K
Q3 25	$32M	$281K
Q4 25	$38M	$13K

Revenue by Geography

Quarter	United States	Europe
Q1 25	$17M	—
Q2 25	$26M	—
Q3 25	$32M	$262K
Q4 25	$38M	$16K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$88M	$3M	$91M
Q2 23	$44M	$2M	$46M
Q3 23	$178M	$12M	$190M
Q4 23	$265M	$1M	$266M
Q1 24	$133M	$37M	$170M
Q2 24	$130M	$88M	$218M
Q3 24	$112M	$18M	$130M
Q4 24	$143M	$6M	$150M
Q1 25	$61M	$931K	$62M
Q2 25	$138M	$16M	$154M
Q3 25	$60M	$198M	$258M
Q4 25	$88M	$154M	$243M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	428M	+6.1%
Q2 23	437M	+2.1%
Q3 23	498M	+13.9%
Q4 23	591M	+18.5%
Q1 24	673M	+13.9%
Q2 24	687M	+2.1%
Q3 24	698M	+1.6%
Q4 24	735M	+5.2%
Q1 25	853M	+16.1%
Q2 25	888M	+4.1%
Q3 25	947M	+6.6%
Q4 25	990M	+4.6%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	—	—
FY 15	$8K	31
FY 16	$537	82
FY 17	$324	139
FY 18	$292	161
FY 19	$291	148
FY 20	$4K	171
FY 21	$2K	587
FY 22	$331	725
FY 23	$990	628
FY 24	$22K	680
FY 25	$1K	79K